Aflivu
Aflibercept biosimilar developed by Apotex. Reference product Eylea.
Brands by market: Aflivu (Canada) · Commercial partner or holder: Apotex
FDAnot listed
EMAnot listed
PMDAnot listed
HCJun 2025approved
CDSCOnot listed
EDEnot listed
Status by market
FDA
United States
Not listed by FDA.
EMA
European Union
Not listed by EMA.
PMDA
Japan
Not listed by PMDA.
HC
Canada · Aflivu
Health CanadaApprovedBrand
Aflivu
Holder or applicant
Apotex INC
Pathway
Biosimilar biologic drug (Notice of Compliance)
Approved
Jun 2025
Application or permission
DIN 02554178, 02554194
Presentations
2 mg
Source
S022
CDSCO
India
Not listed by CDSCO.
EDE
United Arab Emirates
Not listed by EDE.
Chronology
- HCJun 2025Notice of Compliance, Health Canada
Sources
Planning aflibercept biosimilar development?
EvySaif can help assess your regulatory pathway, clinical evidence requirements and market-entry strategy across India, UAE and other target markets.
Talk to a biosimilar regulatory consultantData current to September 2026.